Equilin

Cat. No.:	HY-B1176				
CAS No.:	474-86-2				
Molecular Formula:	C ₁₈ H ₂₀ O ₂				
Molecular Weight:	268.35				
Target:	Estrogen Receptor/ERR				
Pathway:	Vitamin D Related/Nuclear Receptor				
Storage:	Powder	-20°C	3 years		
		4°C	2 years		
	In solvent	-80°C	6 months		
		-20°C	1 month		

®

MedChemExpress

SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (372.65 mM; Need ultrasonic)							
F S	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg			
		1 mM	3.7265 mL	18.6324 mL	37.2648 mL			
		5 mM	0.7453 mL	3.7265 mL	7.4530 mL			
		10 mM	0.3726 mL	1.8632 mL	3.7265 mL			
	Please refer to the solubility information to select the appropriate solvent.							
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (9.32 mM); Clear solution							
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (9.32 mM); Clear solution							
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (9.32 mM); Clear solution							

HO

0

Ĥ

Ĥ

REFERENCES

[1]. David K, et al. Some biological properties of equilin. Biochem J. 1935;29(2):371-377.

[2]. Brinton RD, et al. Equilin, a principal component of the estrogen replacement therapy premarin, increases the growth of cortical neurons via an NMDA receptordependent mechanism. Exp Neurol. 1997;147(2):211-220.

[3]. Ito F, et al. Equilin in conjugated equine estrogen increases monocyte-endothelial adhesion via NF-κB signaling. PLoS One. 2019;14(1):e0211462. Published 2019 Jan 30.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA